Dr. Robert M. Langdon
Claim this profileNebraska Methodist Hospital
Area of expertise
Lung Cancer
Robert M. Langdon has run 8 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Robert M. Langdon has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Nebraska Methodist Hospital
Heartland Oncology And Hematology LLP
Clinical Trials Robert M. Langdon is currently running
Osimertinib
for Non-Small Cell Lung Cancer
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting
1 award
Phase 2
42 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
More about Robert M. Langdon
Clinical Trial Related
11 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Robert M. Langdon has experience with
- Carboplatin
- Pembrolizumab
- Biospecimen Collection
- Paclitaxel
- Osimertinib
- Pemetrexed
Breakdown of trials Robert M. Langdon has run
Lung Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert M. Langdon specialize in?
Robert M. Langdon focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage IV.
Is Robert M. Langdon currently recruiting for clinical trials?
Yes, Robert M. Langdon is currently recruiting for 4 clinical trials in Omaha Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Robert M. Langdon has studied deeply?
Yes, Robert M. Langdon has studied treatments such as Carboplatin, Pembrolizumab, Biospecimen Collection.
What is the best way to schedule an appointment with Robert M. Langdon?
Apply for one of the trials that Robert M. Langdon is conducting.
What is the office address of Robert M. Langdon?
The office of Robert M. Langdon is located at: Nebraska Methodist Hospital, Omaha, Nebraska 68114 United States. This is the address for their practice at the Nebraska Methodist Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.